The mission of the UOHI PET Research Radiochemistry Laboratory is to provide the UOHI, the University of Ottawa and Greater Ottawa region with an onsite core facility that can offer a bench to bedside production/service, providing quality PET Radiopharmaceuticals for research projects in radiochemistry, targetry, animal-models and human imaging. Our goal is to produce novel and established PET Radiopharmaceuticals for innovative research to help understand and guide novel therapies in cardiovascular, kidney, diabetes, oncology and neuroscience diseases. Our lab offers the capability for research on basic radiochemistry to develop novel PET probes with the ultimate goal of translational work in humans to address scientific questions via PET imaging.
Services
| Radiotracer | Application in Cardiology | Other Potential Applications |
|---|---|---|
|
13N-Ammonia |
Myocardial blood flow Animal and human MBF quantification |
Renal perfusion |
|
18F-NaF
|
Arterial calcific/plaque imaging atherosclerosis |
Bone cancer |
|
18F-FTHA |
Free fatty acid uptake PAH patients and animal models |
Other animal models such as MLIP +/+, +/-, -/- mice Skeletal muscle anomalies |
|
11C-HED |
SNS innervations Sleep apnea study Heart failure Atrial fibrillation |
Evaluation of neuronal integrity (examination of tumours of the sympathetic nervous systems) |
|
11C-Acetate |
MBF Myocardial oxygen consumption Myocardial perfusion Oxidative metabolism Cardiac efficiency Renal perfusion |
Prostate cancer Renal cell carcinoma (RCC) Bladder carcinoma Brain tumours Multiple myeloma MBF in kidney |
|
11C-Rolipram |
PDE4 ligand Heart failure |
|
|
18F-FPyKYNE-Losartan |
AT1 receptor uptake Heart failure, hypertension |
Diabetes, renal diseases |
|
18F-HFB |
Cell regenerative therapy |
Cell regenerative therapy Direct Cell Labelling |
|
18F-FPyKYNE-c(RGDyK) |
αVβ3 Integrin Receptor Inflammation |
Inflammation |
|
11C-methyl-Hydroxyfasudil |
Rho-Kinase ligand Inflammation, heart failure, hypertension |
Diabetes |
|
11C-Carfentanil |
Opioid Receptor ligand Mental disorders |
User Fee Schedule: Prices in effect for all grants receiving funding approval after June 30, 2015.
| PER-CLINICAL IMAGING | External User | Internal User | Pilot studies (Maximum 10 doses) | |||
|---|---|---|---|---|---|---|
| Complete synthesis | Shared dose* | Complete synthesis | Shared dose* | Complete synthesis | Shared dose* | |
| NaF |
350 |
20 | 300 | 16 | 240 | 16 |
| NH3 |
250 |
20 | 120 | 16 | 112 | 16 |
| Acetate |
450 |
20 | 400 | 16 | 200 | 16 |
| HED |
800 |
20 | 650 | 16 | 360 | 16 |
| FTHA |
750 |
50 | 700 | 40 | 600 | 40 |
| F-Losartan |
1,400 |
200 | 1,000 | 180 | 800 | 180 |
| Rolipram |
800 |
150 | 700 | 120 | 600 | 120 |
*piggy backed to human clinical research production run
| HUMAN CLINICAL and LARGE ANIMAL IMAGING RESEARCH | Industry rate | External Peer Review |
Internal Peer Review |
Pilot studies (Maximum 10 doses) |
|---|---|---|---|---|
|
NaF |
1,200 | 350 | 300 | 240 |
|
NH3 |
1,000 | 250 | 120 | 112 |
|
Acetate |
800 | 450 | 400 | 200 |
|
HED |
1,350 | 800 | 650 | 360 |
|
FTHA |
2,250 | 750 | 700 | 600 |
|
F-Losartan |
3,400 | 1,400 | 1,000 | 800 |
Prices listed above are subject to change as the development of new tracers is done on a time and materials charge basis.
List of Equipment
Siemens CTI Eclipse HP/RD Hybrid Cyclotron, GE Tracerlab MX (coincidence), GE Tracerlab FX F-N, GE Tracerlab FX C-Pro, CTI ASM Methylation Module, CTI ASM Methyl Iodine Acetate Module, Siemens Explora FDG4, MediSMARTS Radiation Monitoring System, Von Gahlen Hot cells, SRI Gas Chromatography System, Radio-TLC Imaging Scanner, Agilent HPLC, Agilent GC, Multi-Channel Analyzer (MCA), Laminar Flow Hoods and Biological Safety Cabinets, Capintec Dose Calibrators, Mettler Toledo Balance, Millipore Water Deionizer, Analytical and Semi-preparative HPLC Systems (Waters), Rotary Evaporator
Contact
For service requests and more information please contact:
Acting Core Facility Director: Tayebeh Hadizad, PhD
Email: Thadizad@ottawaheart.ca
Facility Staff Members
- Acting Core Facility Director: Dr. Tayebeh Hadizad (thadizad@ottawaheart.ca) develops, produces and analyses novel and established PET Radiopharmaceuticals and oversees lab operations
- Radiochemistry Technologists: Charlotte Warren (cwarren@ottawaheart.ca) and Yin (Daniel) Duan (yduan@ottawaheart.ca) produce and analyze novel and established PET Radiopharmaceuticals
- Cyclotron Engineer: Nebil Shamsudin (nshamsudin@ottawaheart.ca) maintains and services all lab equipment.
- RSO: Jon Aro (jaro@toh.ca) regulates radiation safety.
- Business Manager: Linda Garrard (lgarrard@ottawaheart.ca), invoicing, administration, business.
- Medical Doctor: Rob Beanlands (rbeanlands@ottawaheart.ca), MD, responsible of PERs administered to humans